Overview

VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate safety and effectiveness of the treatment of multiple myeloma with bortezomib in daily practice in the Netherlands.
Details
Lead Sponsor:
Janssen-Cilag B.V.
Treatments:
Bortezomib